Orphan Drugs

Takeovers refocus Sanofi on rare diseases

Read more

Drugs for orphan diseases are no longer rare

Read more

Rare Diseases AbbVie-Shire merger could be a new beginning

Read more

The changing model for rare disease R&D

Read more

Finding a drug for Duchenne muscular dystrophy

Read more

Orphan drug policy: Is the patient being served?

Read more